Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer

BACKGROUND: The combination of gemcitabine (GEM) and S-1, an oral 5-fluorouracil (5-FU) derivative, has been shown to be a promising regimen for patients with unresectable pancreatic cancer. METHODS: Six patients with advanced pancreatic cancer were enrolled in this pharmacokinetics (PK) study. Thes...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakata, Bunzo, Amano, Ryosuke, Nakao, Shigetomi, Tamura, Tatsuro, Shinto, Osamu, Hirakawa, Toshiki, Okita, Yoshihiro, Yamada, Nobuya, Hirakawa, Kosei
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838818/
https://www.ncbi.nlm.nih.gov/pubmed/20181235
http://dx.doi.org/10.1186/1756-9966-29-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838818/
https://www.ncbi.nlm.nih.gov/pubmed/20181235
http://dx.doi.org/10.1186/1756-9966-29-15

Ejemplares similares